These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 38548444)

  • 21. The impact of rifaximin on the hospital burden and infections in patients with hepatic encephalopathy: a retrospective observational study.
    De Graeve J; Vanderstraeten E; Delvaeye T; De Lepeleere S; De Somer T; Van Steenkiste C
    Acta Gastroenterol Belg; 2022; 85(3):433-437. PubMed ID: 35833904
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A Quality Improvement Initiative Reduces 30-Day Rate of Readmission for Patients With Cirrhosis.
    Tapper EB; Finkelstein D; Mittleman MA; Piatkowski G; Chang M; Lai M
    Clin Gastroenterol Hepatol; 2016 May; 14(5):753-9. PubMed ID: 26407750
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A retrospective study of drug utilization and hospital readmissions among Medicare patients with hepatic encephalopathy.
    Vadhariya A; Chen H; Serna O; Zamil H; Abughosh SM
    Medicine (Baltimore); 2020 Apr; 99(16):e19603. PubMed ID: 32311928
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Quality of life as a therapeutic objective in the management of hepatic encephalopathy and the potential role of rifaximin-α.
    Deltenre P; Labenz C; Schuchmann M
    Eur J Gastroenterol Hepatol; 2021 Dec; 33(1S Suppl 1):e1032-e1038. PubMed ID: 34402475
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy of rifaximin in the different clinical scenarios of hepatic encephalopathy.
    Coronel-Castillo CE; Contreras-Carmona J; Frati-Munari AC; Uribe M; Méndez-Sánchez N
    Rev Gastroenterol Mex (Engl Ed); 2020; 85(1):56-68. PubMed ID: 31836274
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical management of type C hepatic encephalopathy.
    Ridola L; Riggio O; Gioia S; Faccioli J; Nardelli S
    United European Gastroenterol J; 2020 Jun; 8(5):536-543. PubMed ID: 32213035
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Chinese guidelines on management of hepatic encephalopathy in cirrhosis.
    Xu XY; Ding HG; Li WG; Jia JD; Wei L; Duan ZP; Liu YL; Ling-Hu EQ; Zhuang H; Hepatology CSO; Association CM
    World J Gastroenterol; 2019 Sep; 25(36):5403-5422. PubMed ID: 31576089
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy and Safety of Rifaximin in the Prevention of Recurrent Episodes of Hepatic Encephalopathy: A Systematic Review and Meta-analysis.
    Elmoursi A; Abdelsattar AT; Khalil F; Shabana H; Zedan HA; El Mancy IM; Ramadan IG; Mostafa S
    Turk J Gastroenterol; 2023 Jun; 34(6):584-592. PubMed ID: 37051626
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Long-term Outcomes of Fecal Microbiota Transplantation in Patients With Cirrhosis.
    Bajaj JS; Fagan A; Gavis EA; Kassam Z; Sikaroodi M; Gillevet PM
    Gastroenterology; 2019 May; 156(6):1921-1923.e3. PubMed ID: 30664879
    [No Abstract]   [Full Text] [Related]  

  • 30. Primary Prophylaxis to Prevent the Development of Hepatic Encephalopathy in Cirrhotic Patients with Acute Variceal Bleeding.
    Higuera-de-la-Tijera F; Servín-Caamaño AI; Salas-Gordillo F; Pérez-Hernández JL; Abdo-Francis JM; Camacho-Aguilera J; Alla SN; Jiménez-Ponce F
    Can J Gastroenterol Hepatol; 2018; 2018():3015891. PubMed ID: 30079329
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Role of rifaximin in the treatment of hepatic encephalopathy].
    Sanchez-Delgado J; Miquel M
    Gastroenterol Hepatol; 2016 Apr; 39(4):282-92. PubMed ID: 26545947
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Nitazoxanide versus rifaximin in preventing the recurrence of hepatic encephalopathy: A randomized double-blind controlled trial.
    Glal KAM; Abd-Elsalam SM; Mostafa TM
    J Hepatobiliary Pancreat Sci; 2021 Oct; 28(10):812-824. PubMed ID: 33768619
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Hepatic Encephalopathy Challenges, Burden, and Diagnostic and Therapeutic Approach.
    Yanny B; Winters A; Boutros S; Saab S
    Clin Liver Dis; 2019 Nov; 23(4):607-623. PubMed ID: 31563214
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Social Impact of Hepatic Encephalopathy.
    Shetty A; Saab EG; Choi G
    Clin Liver Dis; 2024 May; 28(2):273-285. PubMed ID: 38548439
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Rifaximin versus metronidazole in management of acute episode of hepatic encephalopathy: An open labeled randomized clinical trial.
    Mekky MA; Riad AR; Gaber MA; Abdel-Malek MO; Swifee YM
    Arab J Gastroenterol; 2018 Jun; 19(2):76-79. PubMed ID: 29935863
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prevention of hepatic encephalopathy by administration of rifaximin and lactulose in patients with liver cirrhosis undergoing placement of a transjugular intrahepatic portosystemic shunt (TIPS): a multicentre randomised, double blind, placebo controlled trial (PEARL trial).
    de Wit K; Schaapman JJ; Nevens F; Verbeek J; Coenen S; Cuperus FJC; Kramer M; Tjwa ETTL; Mostafavi N; Dijkgraaf MGW; van Delden OM; Beuers UHW; Coenraad MJ; Takkenberg RB
    BMJ Open Gastroenterol; 2020 Dec; 7(1):. PubMed ID: 33372103
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Same- vs Different-Hospital Readmissions in Patients With Cirrhosis After Hospital Discharge.
    Okafor PN; Nnadi AK; Okoli O; Huang AE; Nwaiwu O
    Am J Gastroenterol; 2019 Mar; 114(3):464-471. PubMed ID: 30676364
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Lack of Access to Rifaximin Upon Hospital Discharge Is Frequent and Results in Increased Hospitalizations for Hepatic Encephalopathy.
    Stoll AM; Guido M; Pence A; Gentene AJ
    Ann Pharmacother; 2023 Feb; 57(2):133-140. PubMed ID: 35658580
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Low Predictability of Readmissions and Death Using Machine Learning in Cirrhosis.
    Hu C; Anjur V; Saboo K; Reddy KR; O'Leary J; Tandon P; Wong F; Garcia-Tsao G; Kamath PS; Lai JC; Biggins SW; Fallon MB; Thuluvath P; Subramanian RM; Maliakkal B; Vargas H; Thacker LR; Iyer RK; Bajaj JS
    Am J Gastroenterol; 2021 Feb; 116(2):336-346. PubMed ID: 33038139
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Ammonia - an enduring foe - What evaluating whole body ammonia metabolism can teach us about cirrhosis and therapies treating hepatic encephalopathy.
    Shawcross DL; Thabut D; Amodio P
    J Hepatol; 2023 Aug; 79(2):266-268. PubMed ID: 37178732
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.